Adnexus Pulls Offering

Adnexus Therapeutics Inc., a Waltham, Mass.-based developer of therapeutic proteins, has withdrawn registration for an $86.25 million IPO. The move comes after Adnexus agreed to be acquired by Bristol-Myers Squibb Co. (NYSE: BMY), in a deal that could be valued at just over $500 million. Adnexus has raised $70 million in VC funding from Atlas Venture, Flagship Ventures, HBM BioVentures, Polaris Venture Partners and Venrock.